These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24875194)

  • 1. A randomized, open-label, dose-response study of losartan in hypertensive children.
    Webb NJ; Wells TG; Shahinfar S; Massaad R; Dankner WM; Lam C; Santoro EP; McCrary Sisk C; Blaustein RO
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1441-8. PubMed ID: 24875194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
    Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension: a randomized, parallel-group, multicentre comparison with losartan plus amlodipine.
    Pareek A; Chandurkar NB; Sharma R; Tiwari D; Gupta BS
    Clin Drug Investig; 2010; 30(2):123-31. PubMed ID: 20067330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study.
    Zhu JR; Bai J; Cai NS; Tang B; Fan WH; Guo JZ; Ke YN; Guo JX; Sheng LH; Lu ZY; Cheng NN
    Int J Clin Pract Suppl; 2004 Dec; (145):46-9. PubMed ID: 15617459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, dose-response study of losartan in hypertensive children.
    Shahinfar S; Cano F; Soffer BA; Ahmed T; Santoro EP; Zhang Z; Gleim G; Miller K; Vogt B; Blumer J; Briazgounov I
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):183-90. PubMed ID: 15752945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients.
    Lee YT; Lee CM; Lin CS; Sheu SH; Kuo WK; Tsai CW; Huang LC; Huang HC; Wang JS; Tseng WK
    Int J Clin Pract Suppl; 2004 Dec; (145):40-5. PubMed ID: 15617458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
    Suh SY; Ahn T; Bae JH; Lim DS; Lee SU; Kim YK; Hyon MS; Kim WH; Han KR; Park HK
    Clin Ther; 2014 Oct; 36(10):1402-11. PubMed ID: 25146365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.
    Zhu DL; Bays H; Gao P; Mattheus M; Voelker B; Ruilope LM
    Clin Ther; 2012 Jul; 34(7):1613-24. PubMed ID: 22717420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.
    Oparil S; Abate N; Chen E; Creager MA; Galet V; Jia G; Julius S; Lerman A; Lyle PA; Pool J; Tershakovec AM
    Curr Med Res Opin; 2008 Apr; 24(4):1101-14. PubMed ID: 18328120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension.
    Pareek A; Basavanagowdappa H; Zawar S; Kumar A; Chandurkar N
    Expert Opin Pharmacother; 2009 Jul; 10(10):1529-36. PubMed ID: 19514864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
    Derosa G; Maffioli P; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Guasti L; Sarzani R; Bestetti A; Vanasia M; Gaudio G;
    Cardiovasc Ther; 2017 Feb; 35(1):47-54. PubMed ID: 27860389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.